Acute Invasive Aspergillosis Treatment Market Examination and Industry Growth Till 2026 Which Is Going to Change Industry Future

Acute Invasive Aspergillosis Treatment Market Update: Exceeding Expectations of Key Players That Shows Promising Future


Seattle, WA -- (SBWire) -- 11/20/2019 --Global Acute Invasive Aspergillosis Treatment Market: Competitive Landscape

Key players in the market are focused on R&D of novel antifungal therapies to expand their product portfolio. For instance, F2G, a U.K.-based biotechnology company, is focused on R&D of novel drugs for the treatment of serious fungal diseases such as acute IA.

Major players operating in the global acute invasive aspergillosis treatment market include, Abbott laboratories, Eli Lilly and Company, GlaxoSmithKline, Johnson & Johnson, Mylan Pharmaceuticals, Inc., Novartis AG, AstraZeneca Plc, Pfizer, Inc., Takeda Pharmaceutical Company Ltd., Astellas, and Basilea Pharmaceutica International Ltd.

Request Free PDF Research Report Brochure @

Global Acute Invasive Aspergillosis Treatment Market – Insights

Acute Invasive Aspergillosis (IA) is a rare, opportunistic, and serious infection caused by fungi of the genus Aspergillus. The fungi is found on decaying vegetation and dead leaves. The prevalence of the disease is very low. It affects immunocompromised patients or those suffering from lung diseases. Although majority of the population comes in contact with the fungi, not everyone is vulnerable to IA or acute IA. Aspergillosis can be divided into various types such as invasive aspergillosis, chronic pulmonary aspergillosis, allergic bronchopulmonary aspergillosis, allergic aspergillus sinusitis, aspergilloma, and cutaneous aspergillosis. Weakened immune system, low white blood cell count, presence of lung cavities, asthma or cystic fibrosis, and long-term corticosteroid therapy are some of the risk factors responsible for the development of invasive aspergillosis infection. Voriconazole, Capsofungin, and Amphotericin B are some of the drugs sold for the treatment of aspergillus infection.

Global Acute Invasive Aspergillosis Treatment Market: Drivers

Increasing number of solid organ transplants is expected to boost growth of the global acute invasive aspergillosis treatment market over the forecast period. For instance, according to the Centers for Disease Control and Prevention (CDC), 2017, the epidemiology of invasive aspergillus infection relies upon increasing number of solid organ transplants, stem cell transplant, and newer immunosuppressive agents. According to Organ Procurement and Transplantation Network (OPTN), around 8,500 organ transplants were performed in 2018 and the number is expected to grow in the near future. Patients undergoing organ transplant procedure are often prescribed immunosuppressant medications. This may lead to high vulnerability to acute IA.

Increasing prevalence of AIDS is also expected to boost growth of the market as patients in advanced stages of AIDS are at risk of acquiring acute IA. For instance, according to the World Health Organization (WHO), around 36.7 million people were found suffering from HIV in 2016. Increase use of corticosteroids may adversely impact the immune system, which may further lead to high risk of acquiring acute IA, thereby contributing to growth of the market. According to British Infection Association, the high risk population for invasive aspergillosis includes patients who have undergone allogeneic hematopoietic stem cell transplantation (HSCT), autologous HSCT patients, solid organ transplant patients as well as AIDS patients, patients suffering from acute myeloid leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia, non-Hodgkin lymphoma, and myeloma patients.

Download the Sample copy of Report with Table of Contents and Figures @

Increasing prevalence of cancer is also expected to boost growth of the global acute invasive aspergillosis treatment market. For instance, according to WHO, cancer is the second-leading cause of death globally, and the disease caused 8.8 million deaths in 2015. Increasing approval of drugs for the treatment of acute IA is expected to propel growth of the market. For instance, in 2015, Isavuconazonium, a prodrug form of Isavuconazole was approved by the U.S. FDA. Astellas Pharma US, Inc. markets Isavuconazonium under the brand name Cresemba. Astellas Pharma partnered with Basilea Pharmaceutica International Ltd. for license, co-development, and co-promotion of Isavuconazole (Cresemba), in 2010. In 2014, Basilea Pharmaceutica International Ltd. received full rights to sell Isavuconazole in all markets outside of the U.S. and Canada and Astellas Pharma was responsible for the U.S. and Canada markets. Moreover, Basilea Pharmaceutica Ltd. partnered with Asahi Kasei Pharma for Isavuconazole development, licensing, and marketing in Japan (responsibility of Asahi Kasei), in 2016.

Moreover, patent expiry is expected to offer lucrative growth opportunities for the market players. For instance, the drug Cresemba will expire in 2020, which may aid in price drop and increase in sales volume as generic manufacturers enter the market. Manufacturers such as Amneal Pharmaceuticals, Sandoz Inc., Mylan Pharmaceuticals, Inc., Teva Pharmaceuticals, and Glenmark Pharmaceuticals Ltd. offer generic versions of antifungal medications.

Global Acute Invasive Aspergillosis Treatment Market: Restraints

Increasing cases of resistance to antifungal medications is expected to hinder growth of the global acute invasive aspergillosis treatment market.

Purchase a copy of Acute Invasive Aspergillosis Treatment Market Report:

Acute Invasive Aspergillosis Treatment Market Taxonomy-

Global acute invasive aspergillosis treatment market is segmented on the basis of drug type, distribution channel, and geography.
By Drug Type-
--Amphotericin B

By Distribution Channel-
---Hospital Pharmacies
---Online Pharmacies
---Retail Pharmacies

By Region-
---North America
---Asia Pacific
---Latin America
---Middle East

About Coherent Market Insights
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Media Contact:

Name: Mr. Raj Shah
Phone: US +12067016702
Country: United States
Visit Blog:

Media Relations Contact

Mr. Shah
Coherent Market Insights

View this press release online at: